Possible harmful effects of short course granulocyte colony-stimulating factor in normal donors

Possible harmful effects of short course granulocyte colony-stimulating factor in normal donors.

The initial success of haematopoietic stem cell (HSC) transplants, intended to reconstitute a patient’s bone marrow function after high dose or ‘supralethal’ chemotherapy or chemoradiotherapy, was based on the use of bone marrow derived from either a related or unrelated volunteer donor. However, in the late 1980s it became clear that an alternative was to collect HSCs was from peripheral blood...

The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis.

The effects of daily administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) to eight normal volunteers donating granulocytes for neutropenic relatives undergoing marrow transplantation were studied. Granulocyte donors consisted of seven marrow donors (5 syngeneic, 2 HLA identical) and one haploidentical son who had not donated marrow. All donors were administered da...

Granulocyte colony-stimulating factor.

In the background section of their abstract, Woei-Cherng Shyu and associates state that because granulocyte colony-stimulating factor (G-CSF) has anti-inflammatory and neuroprotective properties and the capacity to mobilize stem cells, it has the potential to be used in treatment of stroke. However, there are limited data about the effects of G-CSF on hemostasis. It has been suggested that G-CS...

Granulocyte colony stimulating factor.

Granulocyte colony-stimulating factor was discovered during attempts to define the normal regulators present in cell supernatants that could induce terminal differentiation of the murine myeloid leukemic cell line WEHI-3B D+. The purification and subsequent cloning of both murine and human G-CSF allowed the normal functions of this molecule to be elucidated and indicated that it was a relativel...

Granulocyte colony-stimulating factor administration and peripheral blood progenitor cells collection in normal donors: analysis of leukapheresis-related side effects.